Breakthrough paves the way for next generation of vision implants
CHALMERS UNIVERSITY OF TECHNOLOGY
IMAGE:
MARIA ASPLUND, WHO LED THE TECHNOLOGY DEVELOPMENT PART OF THE PROJECT AND IS PROFESSOR OF BIOELECTRONICS AT CHALMERS UNIVERSITY OF TECHNOLOGY IN SWEDEN.
view moreCREDIT: CHALMERS UNIVERSITY OF TECHNOLOGY | GABOR RICHTER
A group of researchers from Chalmers University of Technology in Sweden, University of Freiburg and the Netherlands Institute for Neuroscience have created an exceptionally small implant, with electrodes the size of a single neuron that can also remain intact in the body over time – a unique combination that holds promise for future vision implants for the blind.
Often when a person is blind, some or part of the eye is damaged, but the visual cortex in the brain is still functioning and waiting for input. When considering brain stimulation for sight restoration, there needs to be thousands of electrodes going into an implant to build up enough information for an image. By sending electrical impulses via an implant to the visual cortex of the brain, an image can be created, and each electrode would represent one pixel.
“This image would not be the world as someone with full vision would be able to see it. The image created by electrical impulses would be like the matrix board on a highway, a dark space and some spots that would light up depending on the information you are given. The more electrodes that ‘feed’ into it, the better the image would be,” says Maria Asplund, who led the technology development part of the project and is Professor of Bioelectronics at Chalmers University of Technology in Sweden.
The vision implant created in this study can be described as a ‘thread’ with many electrodes placed in a row, one after the other. In the long term you would need several threads with thousands of electrodes connected to each one, and the results of this study are a key step towards such an implant.
The future of vision implants
An electrical implant to improve vision in people with blindness is not a new concept. However, the implant technology currently being explored in human patients is from the 1990s and there are several factors that need to be improved, for example the bulky size, scarring in the brain due to their large size, materials corroding over time and materials being too rigid.
By creating a really small electrode the size of a single neuron, researchers have the potential to fit lots of electrodes onto a single implant and build up a more detailed image for the user. The unique mix of flexible, non-corrosive materials make this a long-term solution for vision implants.
“Miniaturisation of vision implant components is essential. Especially the electrodes, as they need to be small enough to be able to resolve stimulation to large numbers of spots in the ‘brain visual areas’. The main research question for the team was, ‘can we fit that many electrodes on an implant with the materials we have and make it small enough and also effective?’ and the answer from this study was – yes,” says Professor Asplund.
The smaller the size, the worse the corrosion
To create an electrical implant on such a small scale comes with its challenges, especially in a tough environment, such as the human body. The major obstacle is not to make the electrodes small, but to make such small electrodes last a long time in a moist, humid environment. Corrosion of metals in surgical implants is a huge problem, and because the metal is the functional part, as well as the corroding part, the amount of metal is key. The electrical implant that Asplund and her team have created measures in at a miniscule 40 micrometers wide and 10 micrometers thick, like a split hair, with the metal parts being only a few hundred nanometers in thickness. And since there is so little metal in the super tiny vision electrode, it cannot ‘afford’ to corrode at all, otherwise it would stop working.
In the past, this problem has not been possible to solve. But now, the research team have created a unique mix of materials layered up together that do not corrode. This includes a conducting polymer to transduce the electrical stimulation required for the implant to work, to electrical responses in the neurons. The polymer forms a protective layer on the metal and makes the electrode much more resilient to corrosion, essentially a protective layer of plastic covering the metal.
“The conducting polymer metal combination we have implemented is revolutionary for vision implants as it would mean they hopefully could remain functional for the entire implant life-time. We now know it is possible to make electrodes as small as a neuron (nerve cell) and keep this electrode effectively working in the brain over very long timespans, which is promising since this has been missing until now. The next step will be to create an implant that can have connections for 1000s of electrodes,” says Asplund, something that is currently explored within a larger team in the ongoing EU project Neuraviper.
More about: the study method
The method was implemented by the research collaborators at the Netherlands Institute for Neuroscience, where mice were trained to respond to an electrical impulse to the visual cortex of the brain. The study showed that not only could the mice learn to react to the stimulation applied via the electrodes in just a few sessions, but the minimal current threshold for which mice reported a perception was lower than standard metal-based implants. The research team further reported that the functionality of the implant stayed stable over time, for one mouse even until the end of its natural lifespan.
More about the research:
The research has been published in the article: "Flexible Polymer Electrodes for Stable Prosthetic Visual Perception in Mice" published in Advanced Healthcare Materials. It is written by Corinne Orlemann, Christian Boehler, Roxana N. Kooijmans, Bingshuo Li, Maria Asplund and Pieter R. Roelfsema. The authors are active at the Netherlands Institute for Neuroscience, University of Freiburg and Chalmers University of Technology.
For more information, please contact:
Maria Asplund, Professor, Electronics Material and Systems, Microtechnology and Nanoscience, Chalmers University of Technology, Sweden maria.asplund@chalmers.se +46 31 772 41 14
Pieter R. Roelfsema, Department of Vision and Cognition, Netherlands Institute for Neuroscience, Royal Netherlands Academy of Arts and Sciences, Amsterdam, The Netherlands p.roelfsema@nin.knaw.nl
The Chalmers contact person speaks English and Swedish, and is available for live and pre-recorded interviews. At Chalmers, we have podcast studios and broadcast filming equipment on site and would be able to assist a request for a television, radio or podcast interview.
Collage CAPTION: The exceptionally small vision implant created in this study uses electrical impulses to stimulate the visual cortex of the brain, where information is converted into visual impressions, like pixels on a highway matrix board. Lower left corner: figure from the study - electrodes the size of a neuron are placed on implant “threads” as small as half a strand of hair. The implant is made of a non-corrosive material paving the way for a permanent – and more efficient - solution for the blind.
Collage CREDIT: top left eye: Unsplash, lower left: Chalmers University of Technology\ Maria Asplund, right illustration: iStock
NOTE TO THE EDITOR - IMAGES:
The Chalmers Press portal can be accessed here and you can search for any images or videos.
We kindly request credit to be given in the following format where possible:
Image/Graphic/Illustration: Chalmers University of Technology | Name Surname
Images provided in Chalmers University of Technology press releases are, unless specified otherwise, free for download and publication as long as credit is given to the University and the individual creator. Cropping and rescaling of the images is permitted when required for adaptation to the publication’s format, but modifications that would influence the message and content of the original are not. The material is primarily intended for journalistic and informative use, to assist in communication and coverage of Chalmers’ research and education. Commercial usage, for example the marketing of goods and services, is not permitted.
JOURNAL
Advanced Healthcare Materials
METHOD OF RESEARCH
Experimental study
SUBJECT OF RESEARCH
Animals
ARTICLE TITLE
Flexible Polymer Electrodes for Stable Prosthetic Visual Perception in Mice
COI STATEMENT
P.R.R. is cofounder and shareholder of Phosphoenix (Netherlands), which is a neurotechnology start-up.
Participants of pioneering CRISPR gene editing trial see vision improve
OHSU scientist: Results show CRISPR can treat inherited retinal disease, support further research
About 79% of clinical trial participants experienced measurable improvement after receiving experimental, CRISPR-based gene editing that is designed to fix a rare form of blindness, according to a paper published today in the New England Journal of Medicine.
Mark Pennesi, M.D., Ph.D. (OHSU)
“This trial shows CRISPR gene editing has exciting potential to treat inherited retinal degeneration,” said Mark Pennesi, M.D., Ph.D., a corresponding author on the paper, an ophthalmologist and Oregon Health & Science University’s lead scientist for the Phase 1/2 BRILLIANCE trial. “There is nothing more rewarding to a physician than hearing a patient describe how their vision has improved after a treatment. One of our trial participants has shared several examples, including being able to find their phone after misplacing it and knowing that their coffee machine is working by seeing its small lights.
“While these types of tasks might seem trivial to those who are normally sighted, such improvements can have a huge impact on quality of life for those with low vision.”
The BRILLIANCE trial evaluated the safety and effectiveness of EDIT-101, an experimental gene editing treatment developed by Editas Medicine that uses CRISPR technology. The experimental treatment was designed to edit a mutation in the CEP290 gene, which provides instructions to create a protein that is critical for sight.
People with this gene mutation have a rare condition that is commonly called Leber Congenital Amaurosis, or LCA, Type 10, for which there is currently no Food and Drug Administration-approved treatment. LCA’s various types occur in about 2 or 3 out of 100,000 newborns.
Learn more about how OHSU is a leader in eye health care and research.
The OHSU Casey Eye Institute treated the trial’s first participant in early 2020. That procedure also marked the first time that CRISPR had been used to edit genes within the human body, called in vivo gene editing.
The new paper describes the study’s findings through February 2023 and details how the trial’s 14 participants — 12 adults and two children — responded to receiving EDIT-101 in one eye. Key results include:
- 11 participants, about 79%, showed improvement in at least one of four measured outcomes.
- 6 participants, about 43%, showed improvement in two or more outcomes.
- 6 participants, about 43%, reported improved vision-related quality of life.
- 4 participants, about 29%, had clinically meaningful improvement in visual acuity, or how well they could identify objects or letters on a chart.
- There were no serious adverse events related to the treatment.
- Most adverse events were mild or moderate, and all have since been resolved.
Four specific outcomes were used to evaluate the experimental treatment’s effectiveness:
- Visual acuity
- How well participants saw colored points of light while looking into a specialized device, which scientists call a full-field test
- How well participants navigated a research maze with physical objects and varying amounts of light
- How much participants reported experiencing improved quality of life
Further research for a future treatment
In November 2022, trial sponsor Editas Medicine announced that it was pausing the trial’s enrollment and would seek another partner to continue the experimental therapy’s development. Pennesi and colleagues are exploring working with other commercial partners to conduct additional trials, in collaboration with Editas. The researchers hope future studies can examine ideal dosing, whether a treatment effect is more pronounced in certain age groups such as younger patients, and include refined endpoints to measure impacts on activities of daily living.
“This research demonstrates that CRISPR gene therapy for inherited vision loss is worth continued pursuit in research and clinical trials,” said Mass Eye & Ear ophthalmologist Eric Pierce, M.D., Ph.D., who is also a corresponding author. “While more research is needed to determine who may benefit most, we consider the early results promising. To hear from several participants how thrilled they were that they could finally see the food on their plates — that is a big deal. These were individuals who could not read any lines on an eye chart and who had no treatment options, which is the unfortunate reality for most people with inherited retinal disorders.”
“Our patients are the first congenitally blind children to be treated with gene editing, which significantly improved their daytime vision,” said the paper’s third corresponding author, Tomas S. Aleman, M.D., a pediatric ophthalmologist at the Children’s Hospital of Philadelphia and the University of Pennsylvania’s Scheie Eye Institute. “Our hope is that the study will pave the road for treatments of younger children with similar conditions and further improvements in vision. This trial represents a landmark in the treatment of genetic disease, in specific genetic blindness, by offering important alternative treatment when traditional forms of therapy, such as gene augmentation, are not an option.”
“The results from the BRILLIANCE trial provide proof of concept and important learnings for the development of new and innovative medicines for inherited retinal diseases. We’ve demonstrated that we can safely deliver a CRISPR-based gene editing therapeutic to the retina and have clinically meaningful outcomes,” said Editas Medicine Chief Medical Officer Baisong Mei, M.D., Ph.D.
The OHSU Casey Eye Institute is one of five clinical sites that recruited participants for the trial. The other sites are: Bascom Palmer Eye Institute in Miami, Florida; Mass Eye and Ear in Boston, Massachusetts; Scheie Eye Institute at the University of Pennsylvania and Children’s Hospital of Philadelphia; and Kellogg Eye Center in Ann Arbor, Michigan.
More information is also available from Mass Eye and Ear and Penn Medicine.
REFERENCE: Eric A. Pierce, Tomas S. Aleman, Kanishka T. Jayasundera, Bright S. Ashimatey, Keunpyo Kim, Alia Rashid, Michael Jaskolka, Rene L. Myers, Bryon L. Lam, Steven T. Bailey, Jason I. Commander, Andreas K. Lauer, Albert M. Maguire, Mark E. Pennesi, Gene-editing for CEP290-associated Retinal Degeneration, New England Journal of Medicine, May 6, 2023, DOI: 10.1056/NEJMoa2309915, https://www.nejm.org/doi/full/10.1056/NEJMoa2309915.
This research was supported by Editas Medicine, the National Institutes of Health’s National Eye Institute (grants P30 EY014104 and P30 EY010572), Malcolm M. Marquis MD Endowed Fund for Innovation, Research to Prevent Blindness (unrestricted grants to OHSU Casey Eye Institute and University of Pennsylvania’s Scheie Eye Institute), the Irene Heinz Given and John LaPorte Given Endowment, and Hope for Vision.
This content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
In the interest of ensuring the integrity of our research and as part of our commitment to public transparency, OHSU actively regulates, tracks and manages relationships that our researchers may hold with entities outside of OHSU. In regards to this research, Dr. Mark Pennesi has received payments for consulting from Editas Medicine. Review details of OHSU's conflict of interest program to find out more about how we manage these business relationships.
JOURNAL
New England Journal of Medicine
METHOD OF RESEARCH
Randomized controlled/clinical trial
SUBJECT OF RESEARCH
People
ARTICLE TITLE
Gene-editing for CEP290-associated Retinal Degeneration
ARTICLE PUBLICATION DATE
6-May-2024
COI STATEMENT
In the interest of ensuring the integrity of our research and as part of our commitment to public transparency, Oregon Health & Science University actively regulates, tracks and manages relationships that our researchers may hold with entities outside of OHSU. In regards to this research, Dr. Mark Pennesi has received payments for consulting from Editas Medicine. Review details of OHSU's conflict of interest program to find out more about how we manage these business relationships
CRIPSR gene editing leads to improvements in vision for people with inherited blindness, clinical trial shows
Mass Eye and Ear-led phase 1/2 trial, which included 14 participants, found that the first-of-its-kind experimental treatment was safe and efficacious
IMAGE:
PRINCIPAL INVESTIGATOR OF THE BRILLIANCE TRIAL, ERIC PIERCE, MD, PHD, DIRECTOR OF OCULAR GENOMICS INSTITUTE AND BERMAN-GUND LABORATORY FOR THE STUDY OF RETINAL DEGENERATIONS AT MASS EYE AND EAR AND HARVARD MEDICAL SCHOOL
view moreCREDIT: MASS EYE AND EAR
KEY TAKEAWAYS
|
BOSTON- (MAY 6, 2024) Results from a groundbreaking clinical trial of CRISPR gene editing in 14 individuals with a form of inherited blindness show that the treatment is safe and led to measurable improvements in 11 of the participants treated. The phase 1/2 trial called BRILLIANCE, was led by principal investigator Eric Pierce, MD, PhD, of Mass Eye and Ear, a member of the Mass General Brigham healthcare system, and sponsored by Editas Medicine, Inc. Findings are reported May 6th in The New England Journal of Medicine.
“This research demonstrates that CRISPR gene therapy for inherited vision loss is worth continued pursuit in research and clinical trials,” said Pierce, director of Ocular Genomics Institute and Berman-Gund Laboratory for the Study of Retinal Degenerations at Mass Eye and Ear and Harvard Medical School. “While more research is needed to determine who may benefit most, we consider the early results promising. To hear from several participants how thrilled they were that they could finally see the food on their plates –that is a big deal. These were individuals who could not read any lines on an eye chart and who had no treatment options, which is the unfortunate reality for most people with inherited retinal disorders.”
All 14 trial participants, including 12 adults (ages 17 to 63) and two children (ages 10 and 14), were born with a form of Leber Congenital Amaurosis (LCA) caused by mutations in the centrosomal protein 290 (CEP290) gene. They underwent a single injection of a CRISPR/Cas9 genome editing medicine, EDIT-101 in one eye via a specialized surgical procedure. This trial, which included the first patient to ever receive a CRISPR-based investigational medicine directly inside the body, focused primarily on safety with a secondary analysis for efficacy.
No serious treatment or procedure-related adverse events were reported, nor were there any dose-limiting toxicities. For efficacy, the researchers looked at four measures: best-corrected visual acuity (BCVA); dark-adapted full-field stimulus testing (FST), visual function navigation (VNC, as measured by a maze participants completed), and vision-related quality of life.
Eleven participants demonstrated improvements in at least one of those outcomes, while six demonstrated improvement in two or more. Four participants had clinically meaningful improvement in BCVA. Six participants experienced meaningful improvements in cone-mediated vision as indicated by FSTs, five of whom had improvements in at least one of the three other outcomes. Cone photoreceptors are used for daytime and central vision.
“The results from the BRILLIANCE trial provide proof of concept and important learnings for the development of new and innovative medicines for inherited retinal diseases. We’ve demonstrated that we can safely deliver a CRISPR-based gene editing therapeutic to the retina and have clinically meaningful outcomes,” said Baisong Mei, MD, PhD, Chief Medical Officer, Editas Medicine.
Studies like this one show the promise of gene therapy for treating incurable conditions. Mass General Brigham’s Gene and Cell Therapy Institute is helping to translate scientific discoveries made by researchers into first-in-human clinical trials and, ultimately, life-changing treatments for patients.
Exploring CRISPR as an inherited retinal disorder treatment
Mutations in the CEP290 gene are the leading cause of inherited blindness taking place during the first decade of life. The mutations cause rod and cone photoceptors in the eye’s retina to function improperly, which after some time will lead to irreversible vision loss. Pierce compares it to a small part of an engine breaking down, which eventually leads the entire engine to falter.
CRISPR-Cas9 is a gene editing toolkit that acts as a GPS-guided scissor to cut a portion of the mutated genome to leave a functional gene. For inherited blindness, the goal was to inject CRISPR to reach the eye’s retina to restore the ability to produce the gene and protein responsible for light-sensing cells.
The CEP290 gene is larger than what traditional adeno-associated virus (AAV) vector gene therapies, including one FDA-approved for a different type of inherited vision loss, can accommodate. The genome editing company Editas Medicine began exploring how to tackle the CEP290 mutation in 2014, conducting preclinical studies to determine whether a gene editing approach like CRISPR-Cas9 might be feasible to target these large gene mutations. This work led to the BRILLIANCE trial, which began in mid-2019.
The first patient to receive a CRISPR treatment inside the body (in vivo) took place at the Casey Eye Institute at Oregon Health & Science University (OHSU), under the leadership of Mark Pennesi, MD, PhD.
“This trial shows CRISPR gene editing has exciting potential to treat inherited retinal degeneration,” Pennesi said. “There is nothing more rewarding to a physician than hearing a patient describe how their vision has improved after a treatment. One of our trial participants has shared several examples, including being able to find their phone after misplacing it and knowing that their coffee machine is working by seeing its small lights. While these types of tasks might seem trivial to those who are normally sighted, such improvements can have a huge impact on quality of life for those with low vision.”
The second patient was treated at Mass Eye and Ear in September 2020, following delays caused by the COVID-19 pandemic. Additional participants were treated across three other trial sites: Bascom Palmer Eye Institute, W.K. Kellogg Eye Center, and Scheie Eye Institute at the Children’s Hospital of Philadelphia (CHOP) and the Hospital of the University of Pennsylvania. Two adults received low-dose therapy, five received mid-dose, and another five received a high-dose treatment. Two children, treated at CHOP under the leadership of Tomas S. Aleman, MD, received a mid-dose treatment.
“Our patients are the first congenitally blind children to be treated with gene-editing, which significantly improved their daytime vision. Our hope is that the study will pave the road for treatments of younger children with similar conditions and further improvements in vision,” said Aleman, the Irene Heinz-Given and John LaPorte Research Professor in Ophthalmology at Penn Medicine with the Scheie Eye Institute and a pediatric ophthalmologist at CHOP who served as a site principal investigator and study co-author. “This trial represents a landmark in the treatment of genetic diseases, in specific, genetic blindness, by offering an important alternative treatment, when traditional forms of gene therapy, such as gene augmentation, are not an option.”
Participants were monitored every three months for one year, and then followed less frequently for two additional years. At visits, they would undergo a series of serum and vision tests to examine safety and efficacy outcome measures.
In November 2022, Editas paused enrollment on the BRILLIANCE trial. Pierce and colleagues are exploring working with other commercial partners to conduct additional trials, in collaboration with Editas. The researchers hope future studies can examine ideal dosing, whether a treatment effect is more pronounced in certain age groups such as younger patients, and include refined endpoints to measure the effects of improved cone function on activities of daily living.
Authorship: The senior corresponding author of this study was Eric A. Pierce, MD, PhD (Mass Eye and Ear), and Tomas S. Aleman, MD (CHOP) and Mark E. Pennesi, MD, PhD (OHSU) were co-corresponding authors. Additional co-authors include Kanishka T. Jayasundera, MD (Kellogg), Bright S. Ashimatey, OD, PhD (Editas), Keunpyo Kim, PhD (Editas), Alia Rashid, MD (Editas), Michael C. Jaskolka, PhD (Editas), Rene L. Myers, PhD (Editas), Byron L. Lam, MD (Bascom Palmer), Steven T. Bailey, MD (OHSU), Jason I. Comander, MD, PhD (Mass Eye and Ear), Andreas K. Lauer, MD (OHSU), Albert M. Maguire, MD (CHOP).
Disclosures: Disclosure forms provided by the author are available with the full text of the journal article at NEJM.org
Funding: This research was funded by Editas medicine. This research was also supported by the National Institute of Health P30 EY014104 core grant to Mass Eye and Ear, P30 EY010572 core grant, the Malcolm M. Marquis MD Endowed Fund for Innovation, and an unrestricted grants from Research to Prevent Blindness to Casey Eye Institute and the Scheie Eye Institute. Additional support was provided by the Irene Heinz Given and John La Porte Given Endowment, and Hope for Vision.
Paper cited: Pierce, EA et al. “Gene-editing for CEP290-associated Retinal Degeneration” NEJM DOI: 10.1056/NEJMoa2309915.
Jason Comander, MD, PhD, director of the Inherited Retinal Disorders Service at Mass Eye and Ear, examines the CRISPR-based medicine prior to performing a surgery of the novel treatment in September 2020, at Mass Eye and Ear in Boston.
Infographic explaining the phase 1/2 results of the BRILLIANCE trial.
Jason Comander, MD, PhD, performs the procedure to deliver the CRISPR-based medicine as part of the BRILLIANCE trial in September 2020 at Mass Eye and Ear.
About Mass Eye and Ear
Massachusetts Eye and Ear, founded in 1824, is an international center for treatment and research and a teaching hospital of Harvard Medical School. A member of Mass General Brigham, Mass Eye and Ear specializes in ophthalmology (eye care) and otolaryngology–head and neck surgery (ear, nose and throat care). Mass Eye and Ear clinicians provide care ranging from the routine to the very complex. Also home to the world's largest community of hearing and vision researchers, Mass Eye and Ear scientists are driven by a mission to discover the basic biology underlying conditions affecting the eyes, ears, nose, throat, head and neck and to develop new treatments and cures. In the 2023–2024 “Best Hospitals Survey,” U.S. News & World Report ranked Mass Eye and Ear #4 in the nation for eye care and #7 for ear, nose and throat care. For more information about life-changing care and research at Mass Eye and Ear, visit our blog, Focus, and follow us on Instagram, Twitter and Facebook.
JOURNAL
New England Journal of Medicine
METHOD OF RESEARCH
Randomized controlled/clinical trial
SUBJECT OF RESEARCH
People
ARTICLE TITLE
Gene Editing for CEP290- Associated Retinal Degeneration
ARTICLE PUBLICATION DATE
6-May-2024
COI STATEMENT
Disclosure forms provided by the author are available with the full text of the journal article at NEJM.org
No comments:
Post a Comment